about
Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the LiteratureTargeted Therapies for Brain Metastases from Breast CancerKSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTLIn-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid β production and clearance.Breast Cancer Patients Have Greatly Benefited from the Progress in Molecular Oncology.The interplay between HPIP and casein kinase 1α promotes renal cell carcinoma growth and metastasis via activation of mTOR pathway.Impacts of the mTOR gene polymorphisms rs2536 and rs2295080 on breast cancer risk in the Chinese population.Targeted therapies in breast cancer: New challenges to fight against resistance.Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis.Non-invasive (89)Zr-Transferrin PET Shows Improved Tumor Targeting Compared to (18)F-FDG PET in MYC-overexpressing Human Triple Negative Breast Cancer.Increased ceramide production sensitizes breast cancer cell response to chemotherapy.Modelling the molecular mechanisms of aging.Chemosensitivity enhancement toward arsenic trioxide by inhibition of histone deacetylase in NB4 cell line.New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease.Metastatic breast cancer: The Odyssey of personalization.The PI3K Pathway: Background and Treatment Approaches.Targeted Treatment of Brain Metastases.'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling.PI3K-Akt-mTOR axis sustains rotavirus infection via the 4E-BP1 mediated autophagy pathway and represents an antiviral target.Combination of mTOR and MAPK Inhibitors-A Potential Way to Treat Renal Cell Carcinoma.The crossroads of breast cancer progression: insights into the modulation of major signaling pathways.Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin.Celastrus orbiculatus extracts induce cell cycle arrest and apoptosis in human esophageal squamous carcinoma ECA-109 cells in vitro via the PI3K/AKT/mTOR signaling pathway.Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.Mechanism of anticancer action of novel berenil complex of platinum(II) combined with anti-MUC1 in MCF-7 breast cancer cells.Profiling the interactome of protein kinase C ζ by proteomics and bioinformatics.Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors.Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma.Revisiting the IGF-1R as a breast cancer target.DNA Mutations May Not Be the Cause of Cancer.Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies.GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling.Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance.The "Yin and Yang" of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers
P2860
Q28067445-9E4598A7-70CC-488D-83CA-8C9CAF1C5F22Q28068154-116C07BA-3D3C-4D68-97FA-A16A9CEEC170Q28831422-09D7A355-87F1-4787-9CC4-CA1DF503EF51Q33601377-F0156112-E340-4625-BF59-C2BC4F1FE29BQ33674656-EB734D75-DE2E-4BE2-8187-5B5DDE96CADFQ36115392-D76A9D7C-8DAD-4C68-A9B0-7ACE7300C53FQ36147954-CFCA1A6C-A036-4669-84F8-A234D3433BD3Q37426764-017E1559-D685-4ED4-96E8-4213C83CC62DQ37629003-236F08CF-5EDA-42A7-9CE2-8ADDBD55A323Q37743048-FAEC51F4-752C-41B0-BACA-62903F87C394Q38604547-0ABD600E-2BEE-4293-82CA-50CBCE2D318AQ38605112-5C94F3FD-6FED-4F16-9B88-FD81895810ABQ38709652-A9F67578-33DC-497A-B2EA-CE4789A6A829Q38769316-D4AEB1A3-9323-4DB9-B6F6-FE9052BB6A69Q38770298-1B69EE2E-9766-4866-AF8B-8A9FCDC4CCE3Q38849186-0FAFE694-F3A9-4A2A-B2E9-B2CDFA605CD0Q38901163-5A681321-79DB-4617-8220-1BEB27B06C54Q39147158-1081C40C-1F45-4120-8383-51A07D17438FQ39192200-3399E14C-0082-4E69-9059-31A63532D8C3Q39453727-5F334EB6-FF7D-4CC0-A3B8-735C1390BCEEQ40213848-57F481A3-B7FB-4333-A4EB-66CCA1250286Q42705608-6F8E1EB9-59A7-4E12-8D02-B451E37A7B90Q47167746-DA9C30CC-36DF-4367-A80A-0E15CA0217AFQ47217432-3B606DDF-16DB-4B5E-997B-8C105E6CDD81Q49418426-27E36A26-0F05-48D7-9B76-79F2CEFC1372Q49952154-9A538C91-9387-4577-AF70-4037F647B2D3Q50053566-363E1F73-B79A-4DB2-B539-77BFB582B53BQ50330788-AED5BA5C-F6A0-4094-9139-9D2B07E9414DQ52640415-007C3DF4-2FA6-4B5E-A436-24363A23F4DFQ52673571-9EE1565E-0ECB-4A1B-BB9F-D16D7FE9E16DQ52686152-7C4F2DAD-5294-4005-A0CB-0CE2136578A4Q53725947-D46325BB-A65A-4269-A4F0-EE30BC6B90FAQ55287222-8A41795F-B7BC-4C14-B096-7489516EC783Q55446160-B91EFEFC-4C6E-4A16-9E6C-4850F3CB12D9Q55480165-20622535-07B5-42E3-B6E4-C31A5719D921Q58702607-13040AEE-81A0-4A53-9C4D-519538F1A0D0
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
PI3K/Akt/mTOR inhibitors in breast cancer
@ast
PI3K/Akt/mTOR inhibitors in breast cancer
@en
PI3K/Akt/mTOR inhibitors in breast cancer
@nl
type
label
PI3K/Akt/mTOR inhibitors in breast cancer
@ast
PI3K/Akt/mTOR inhibitors in breast cancer
@en
PI3K/Akt/mTOR inhibitors in breast cancer
@nl
prefLabel
PI3K/Akt/mTOR inhibitors in breast cancer
@ast
PI3K/Akt/mTOR inhibitors in breast cancer
@en
PI3K/Akt/mTOR inhibitors in breast cancer
@nl
P2860
P3181
P1476
PI3K/Akt/mTOR inhibitors in breast cancer
@en
P2093
Joycelyn Jx Lee
P2860
P304
P3181
P356
10.7497/J.ISSN.2095-3941.2015.0089
P407
P50
P577
2015-12-01T00:00:00Z